+A -A

Tabela:
Comparative View:

4Q17 Create chart
Net sales revenues 1,102,632
Change in Fair Value of Biological Assets 93,603
Cost of Goods Sold -695,393
Depreciation / Amortization / exhaustion -99,996
Exhaustion of biological assets -31,284
Gross Profit 369,562
Selling Expenses -172,905
General and Administrative Expenses -37,117
Management Compensation -4,048
Other Operating Compensation -20,671
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity 134,821
Financial Income 27,600
Financial Expenses -81,885
Income Before Income Tax and Social Contribution 80,536
Income and social contribution taxes - current -7,940
Income Tax and Social Contribution - Deferred 12,022
Effect profit from discontinued operation 0
Net Income 84,618
Recurring Net Income 112,936
Recurring EBITDA 228,870
EBITDA Margin 20.8 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza